CoChat
Sign Up
Cited by 31Smoking Behavior and CessationChronic Obstructive Pulmonary Disease (COPD) ResearchSubstance Abuse Treatment and Outcomes

Helping patients with ESRD and earlier stages of CKD to quit smoking

Open access
Formanek, Perry, Salisbury-Afshar, Elizabeth, Afshar, Majid·2018·American Journal of Kidney Diseases
DOI 10.1053/j.ajkd.2018.01.057PMC PMC6057817
Open this paper in CoChat — free account

Abstract

Among the many adverse effects of tobacco exposure is the increased risk for progression of kidney disease. Individuals with chronic kidney disease (CKD), who already face increased cardiovascular event rates compared to the general population, are at even greater risk if they smoke. Despite these risks and the increased focus on smoking cessation in the general population in recent years, national guidelines have not specifically targeted individuals with CKD. There are similarly sparse data specific to individuals with CKD regarding the safety and efficacy of evidence-based smoking cessation modalities. This review aims to identify the risks of nicotine dependence in individuals with CKD and the potential benefits of smoking cessation; discuss current strategies for smoking cessation, including behavioral and pharmacologic therapies such as varenicline; and extrapolate these interventions to the unique challenges of this population. Much of the data presented stem from evidence for the general population but are described with additional consideration in dosing of nicotine replacement therapy, as well as non-nicotine pharmacotherapy and treatment modality for individuals with CKD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.ajkd.2018.01.057

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Use of e-cigarettes has increased over time, their safety especially with regard to CVD has been questioned, and their effects on kidney disease are unknown.

    “Although use of e-cigarettes has increased over time, their safety, especially with regard to CVD, has been questioned, and their effects on kidney disease are unknown.”

    From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [185]

    The Background section (page unavailable) describes growing e-cigarette use. The Non-combustible products section (page unavailable) questions their safety, citing potential harm and limited knowledge of long-term effects. It does not specifically address cardiovascular safety or state that their effects on kidney disease are unknown. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • Although dedicated trials are lacking in those with CKD, these interventions are likely to confer similar benefits in those with diabetes and CKD.

    “Although dedicated trials are lacking in those with CKD, these interventions are likely to confer similar bene fi ts in those with diabetes and CKD.”

    From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [185]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 83 · Cited by 31

Research works printed but not linked: 65

  1. [2]Lim SS Vos T Flaxman AD A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 The Lancet 2012 380 9859 2224 2260 PMC4156511 23245609
  2. [3]Richardson A Pearson J Xiao H Stalgaitis C Vallone D Prevalence, harm perceptions, and reasons for using noncombustible tobacco products among current and former smokers Am J Public Health 2014 104 8 1437 1444 24922154 PMC4103237
  3. [5]Xia J Wang L Ma Z Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies Nephrol Dial Transplant 2017 32 3 475 487 28339863
  4. [6]Longenecker JC Traditional Cardiovascular Disease Risk Factors in Dialysis Patients Compared with the General Population: The CHOICE Study Journal of the American Society of Nephrology 2002 13 7 1918 1927 12089389
  5. [7]Lhotta K Rumpelt HJ Konig P Mayer G Kronenberg F Cigarette smoking and vascular pathology in renal biopsies Kidney Int 2002 61 2 648 654 11849408
  6. [8]Orth SR Effects of Smoking on Systemic and Intrarenal Hemodynamics: Influence on Renal Function Journal of the American Society of Nephrology 2004 15 90010 58S 63 14684675
  7. [9]Orth SR Smoking–a renal risk factor Nephron 2000 86 1 12 26 10971149
  8. [10]Bergman BC Perreault L Hunerdosse D Novel and reversible mechanisms of smoking-induced insulin resistance in humans Diabetes 2012 61 12 3156 3166 22966072 PMC3501865
  9. [11]Xu H Huang X Arnlov J Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4 Clin J Am Soc Nephrol 2014 9 4 690 697 24436478 PMC3974352
  10. [12]van der Vaart H Postma DS Timens W ten Hacken NH Acute effects of cigarette smoke on inflammation and oxidative stress: a review Thorax 2004 59 8 713 721 15282395 PMC1747102
  11. [13]Pecoits-Filho R Heimbürger O Bárány P Associations between circulating inflammatory markers and residual renal function in CRF patients American Journal of Kidney Diseases 2003 41 6 1212 1218 12776273
  12. [14]Minami J Ishimitsu T Matsuoka H Effects of Smoking Cessation on Blood Pressure and Heart Rate Variability in Habitual Smokers Hypertension 1999 33 1 Pt 2 586 590 9931170
  13. [15]Poulsen PL Ebbehøj E Hansen KW Mogensen CE Effects of Smoking on 24-h Ambulatory Blood Pressure and Autonomic Function in Normoalbuminuric Insulin-Dependent Diabetes Mellitus Patients Am J Hypertens 1998 11 9 1093 1099 9752895
  14. [16]Klag MJ Whelton PK Randall BL Blood pressure and end-stage renal disease in men N Engl J Med 1996 334 1 13 18 7494564
  15. [17]Tozawa M Iseki K Iseki C Kinjo K Ikemiya Y Takishita S Blood pressure predicts risk of developing end-stage renal disease in men and women Hypertension 2003 41 6 1341 1345 12707291
  16. [18]Hsu C-Y McCulloch CE Darbinian J Go AS Iribarren C Elevated Blood Pressure and Risk of End-stage Renal Disease in Subjects Without Baseline Kidney Disease Arch Intern Med 2005 165 8 923 928 15851645
  17. [19]Peterson JCAS Burkart JM Greene T Hebert LAHL King AJ Klahr S Massry SGSJ for the Modification of, Group DiRDMS Blood pressure control, proteinuria, and the progression of renal disease Ann Intern Med 1995 123 10 754 762 7574193
  18. [20]Campese V Bigazzi R The role of hypertension in the progression of renal diseases AJKD 1991 17 5 43 47 2024672
  19. [21]Benck U Clorius J Zuna I Ritz E Renal hemodynamic changes during smoking-Effects of adrenoreceptor blockade European Journal of Clinical Investigation 1999 29 12 1010 1018 10583448
  20. [22]Orth SR Cigarette smoking- an important renal risk factor - far beyond carcinogenesis Tobacco Induced Diseases 2002 1 2 137 155 19570254 PMC2671650
  21. [23]Sarnak MJ Levey AS Schoolwerth AC Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 2003 108 17 2154 2169 14581387
  22. [24]Ockene IS Miller NH Cigarette Smoking, Cardiovascular Disease, and Stroke: A Statement for Healthcare Professionals From the American Heart Association Circulation 1997 96 9 3243 3247 9386200
  23. [25]Chuahirun T Hudson C Seipel T Cigarette Smoking Exacerbates and Its Cessation Ameliorates Renal Injury in Type 2 Diabetes The American Journal of the Medical Sciences 2004 327 2 57 67 14770020
  24. [26]Raymond CB Naylor HK Smoking cessation in patients with chronic kidney disease The CANNT Journal 2010 20 4 24 29 21319580
  25. [27]Schiffl H Lang S Fischer R Stopping smoking slows accelerated progression of renal failure in primary renal disease J Nephrol 2002 15 3 270 274 12113598
  26. [28]Verbiest M Brakema E van der Kleij R National guidelines for smoking cessation in primary care: a literature review and evidence analysis NPJ Prim Care Respir Med 2017 27 1 2 28108747 PMC5434788
  27. [29]Stead LF Koilpillai P Lancaster T Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation Cochrane Database Syst Rev 2015 10 CD009670 26457723
  28. [31]Jamal A Dube SR Malarcher AM Shaw L Engstrom MC Tobacco Use Screening and Counseling During Physician Office Visits Among Adults — National Ambulatory Medical Care Survey and National Health Interview Survey, United States, 2005–2009 MMWR 2012 61 2 38 45 22695462
  29. [32]Adler NE Stead WW Patients in context–EHR capture of social and behavioral determinants of health N Engl J Med 2015 372 8 698 701 25693009
  30. [34]Solberg LI Boyle RG Davidson G Magnan S Carlson CL Patient Satisfaction and Discussion of Smoking Cessation During Clinical Visits Mayo Clinic Proceedings 2001 76 2 138 143 11213301
  31. [35]The Tobacco Use and Dependence Clinical Practice Guideline Panel S, and Consortium Representatives A Clinical Practice Guideline for Treating Tobacco Use and Dependence: A US Public Health Service Report JAMA 2000 283 24 3244 3254 10866874
  32. [36]Hughes JR Keely J Naud S Shape of the relapse curve and long-term abstinence among untreated smokers Addiction 2004 99 1 29 38 14678060
  33. [37]Norcross JC Krebs PM Prochaska JO Stages of change J Clin Psychol 2011 67 2 143 154 21157930
  34. [38]Prochaska JO DiClemente CC Stages and processes of self-change of smoking: Toward an integrative model of change Journal of Consulting and Clinical Psychology 1983 51 3 390 395 6863699
  35. [39]Prochaska JO Velicier WF Rossi JS Goldstein MG Stages of change and decisional balance for 12 problem behaviors Health Psychology 1994 13 1 39 46 8168470
  36. [41]Lindson-Hawley N Thompson TP Begh R Motivational interviewing for smoking cessation Cochrane Database Syst Rev 2015 3 CD006936 25726920
  37. [42]Parkes G Greenhalgh T Griffin M Dent R Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial BMJ 2008 336 7644 598 600 18326503 PMC2267989
  38. [43]Clinical Practice Guideline Treating Tobacco U, Dependence Update Panel L, Staff A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report Am J Prev Med 2008 35 2 158 176 18617085 PMC4465757
  39. [49]Chaiton M Diemert L Cohen JE Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers BMJ Open 2016 6 6 e011045 PMC4908897 27288378
  40. [50]Harris KK Zopey M Friedman TC Metabolic effects of smoking cessation Nat Rev Endocrinol 2016 12 5 299 308 26939981 PMC5021526
  41. [51]Farley AC Hajek P Lycett D Aveyard P Interventions for preventing weight gain after smoking cessation Cochrane Database Syst Rev 2012 1 CD006219 22258966
  42. [52]Stead LF Perera R Bullen C Nicotine replacement therapy for smoking cessation Cochrane Database Syst Rev 2012 11 CD000146 18253970
  43. [54]Manley HJ Stack NM Smoking Cessation Therapy Considerations for Patients with Chronic Kidney Disease Nephrology Nursing Journal 2008 35 4 357 364 18782998
  44. [55]Worrall SPR Almond MK Dhillon S Pharmacokinetics of bupropion and its metabolites in hemodialysis patients who smoke Nephron Clin Pract 2004 97 3 83 89 15292684
  45. [56]Turpeinen M Koivuviita N Tolonen A Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites Br J Clin Pharmacol 2007 64 2 165 173 17335546 PMC2000634
  46. [58]Anthenelli RM Benowitz NL West R Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial The Lancet 2016 387 10037 2507 2520 27116918
  47. [60]Anthenelli RM Benowitz NL West R Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial Lancet 2016 387 10037 2507 2520 27116918
  48. [61]Steinberg MB Greerhaus S Schmelzer AC Triple-combination pharmacotherapy for medically ill smokers- a randomized trial Ann Intern Med 2009 150 7 447 455 19349630
  49. [62]Hajek P Smith KM Dhanji A-R McRobbie H Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomized controlled trial BMC Medicine 2013 11 140 PMC4231450 23718718
  50. [63]Ebbert JO Hatsukami DK Croghan IT Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial JAMA 2014 311 2 155 163 24399554 PMC3959999
  51. [64]Zalai D Szeifert L Novak M Psychological distress and depression in patients with chronic kidney disease Semin Dial 2012 25 4 428 438 22809005
  52. [65]Kimmel PL Cukor D Cohen SD Peterson RA Depression in end-stage renal disease patients: a critical review Adv Chronic Kidney Dis 2007 14 4 328 334 17904499
  53. [67]Hartmann-Boyce J McRobbie H Bullen C Begh R Stead LF Hajek P Electronic cigarettes for smoking cessation Cochrane Database Syst Rev 2016 9 CD010216 27622384 PMC6457845
  54. [68]Bullen C Howe C Laugesen M Electronic cigarettes for smoking cessation: a randomised controlled trial The Lancet 2013 382 9905 1629 1637 24029165
  55. [69]Kalkhoran S Glantz SA E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis The Lancet Respiratory Medicine 2016 4 2 116 128 26776875 PMC4752870
  56. [70]Farsalinos KE Kistler KA Gillman G Voudris V Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins Nicotine Tob Res 2015 17 2 168 174 25180080 PMC4892705
  57. [71]Chapman AB Johnson AM Gabow PA Schrier RW Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease J Am Soc Nephrol 1994 5 6 1349 1354 7894001
  58. [72]Ward M Studenski S Clinical prognostic factors in lupus nephritis: The importance of hypertension and smoking Arch Intern Med 1992 152 10 2082 2088 1417382
  59. [73]Foley RN Herzog CA Collins AJ Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study Kidney Int 2003 63 4 1462 1467 12631362
  60. [74]Stengel B Couchoud C Cénée S Hémon D Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies Kidney International 2000 57 6 2519 2526 10844621
  61. [75]Grams ME Coresh J Segev DL Kucirka LM Tighiouart H Sarnak MJ Vascular disease, ESRD, and death: interpreting competing risk analyses Clin J Am Soc Nephrol 2012 7 10 1606 1614 22859747 PMC3463208
  62. [76]Ricardo AC Anderson CA Yang W Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study Am J Kidney Dis 2015 65 3 412 424 25458663 PMC4339665
  63. [77]Staplin N Haynes R Herrington WG Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP) Am J Kidney Dis 2016 68 3 371 380 27118687 PMC4996629
  64. [82]van Zyl-Smit RN Allwood B Stickells D South African tobacco smoking cessation clinical practice guideline S Afr Med J 2013 103 11 869 876 24148176
  65. [83]West R McNeill A Raw M Smoking cessation guidelines for health professionals- an update Thorax 2000 55 12 987 999 11083883 PMC1745657

Authors
Formanek, P., Salisbury-Afshar, E., & Afshar, M.
Affiliations
Loyola University Medical Center (US)
Corresponding author
Formanek, Perry
ORCID
Venue
American Journal of Kidney Diseases
Publisher
Elsevier BV
Published
2018-08
Volume
72
Issue
2
Pages
255-266
ISSN
0272-6386 (ISSN-L)
DOI
10.1053/j.ajkd.2018.01.057
PMC
PMC6057817
OpenAlex
W2797563622
Cited by
31
References
83
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 6 · 2020: 3 · 2019: 1 · 2018: 2
FWCI
2.06
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Kidney Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Alcohol Abuse and Alcoholism (K23AA024503)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
smoking cessation, chronic kidney disease, end-stage renal disease, nicotine dependence, varenicline, nicotine replacement therapy, kidney disease progression, cardiovascular risk
MeSH terms
Aged, Humans, Kidney Failure, Chronic, Male, Patient Education as Topic, Tobacco Use Disorder, Smoking Cessation, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review